Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Naseer Alnakhli
 -- 1951 2023-12-03 20:23:19 |
2 format correct
Catherine Yang
 Meta information modification 1951 2023-12-04 01:46:55 |

Video Upload Options

We provide professional Video Production Services to translate complex research into visually appealing presentations. Would you like to try it?
No, upload directly Yes

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Naseer, A.; Mo, S.; Olsen, S.C.; Mccluskey, B. Brucella melitensis Vaccines. Encyclopedia. Available online: https://encyclopedia.pub/entry/52287 (accessed on 17 November 2024).
Naseer A, Mo S, Olsen SC, Mccluskey B. Brucella melitensis Vaccines. Encyclopedia. Available at: https://encyclopedia.pub/entry/52287. Accessed November 17, 2024.
Naseer, Alnakhli, Salman Mo, Steven C. Olsen, Brian Mccluskey. "Brucella melitensis Vaccines" Encyclopedia, https://encyclopedia.pub/entry/52287 (accessed November 17, 2024).
Naseer, A., Mo, S., Olsen, S.C., & Mccluskey, B. (2023, December 03). Brucella melitensis Vaccines. In Encyclopedia. https://encyclopedia.pub/entry/52287
Naseer, Alnakhli, et al. "Brucella melitensis Vaccines." Encyclopedia. Web. 03 December, 2023.
Brucella melitensis Vaccines
Edit
This entry is adapted from the peer-reviewed paper 10.3390/agriculture13112137

Brucella melitensis is recognized as one of the predominant zoonotic pathogens globally. Live-attenuated vaccine Rev 1 is currently the most effective vaccine for controlling B. melitensis in small ruminants. While Brucella inactivated, nanoparticle, and subunit vaccines are less effective and require multiple doses, live-attenuated vaccines are less expensive and more efficacious. Several drawbacks are associated with the administration of current attenuated B. melitensis vaccines, including interference with serological diagnostic tests, inducing abortion in pregnant animals, shedding in milk, and zoonotic infections in humans. 

brucellosis B. melitensis vaccines Rev 1 small ruminants

1. Introduction

Because of the high number of human cases identified each year, Brucella melitensis is one of the most important zoonotic pathogens worldwide [1]. Three biovars of B. melitensis, 1, 2, and 3, are known but are not known to differ in virulence [2]. Goats and sheep are the most common natural hosts of B. melitensis. The most common route of transmission in natural hosts is most likely through oral or respiratory mucosa. The predilection of B. melitensis for colonization of trophoblasts in the placenta and fetal tissues leads to fetal stress or death and the induction of premature parturition (abortion) [1][2]. Although abortion is the primary clinical sign, it can be minimal in chronically infected herds. In addition to the shedding of high numbers of bacteria after abortion or birth of infected lambs or kids, some animals shed high levels of bacteria in the milk. Bacterial shed after parturition poses a risk for lateral transmission to other animals [2], whereas shedding in milk is a risk for vertical transmission. It is worth noting that contaminated milk can contribute to the human transmission of this infection. Failure to prevent exposure of uninfected animals to those shedding Brucella makes control of the disease difficult. Co-housing of ruminant species is a risk factor for brucellosis transmission [3]. Camels are highly susceptible to B. melitensis infection and play an important role in its epidemiology in some countries [4]. In other countries, endemic infection has been identified in Alpine ibex (Capra ibex) and chamois (Rupicapra rupicapra) and has occasionally led to brucellosis spillover into humans and domestic livestock [5].
Since the beginning of the 20th century, researchers have been searching for vaccines to prevent brucellosis in animals and humans [6]. Both live and inactive vaccines have been developed, but live-attenuated vaccines have been found to be better at inducing protective immunity against this intracellular pathogen [7]. Although a variety of killed vaccines have been developed, their success and acceptance have been limited, and none have induced the level of protection of live-attenuated vaccines. Historically, the first Brucella vaccine using killed Brucella was made in 1906 by Eyre who used it to vaccinate 51 soldiers [7]. Two killed vaccines that had more widespread use were B. melitensis H38 and B. abortus strain 45/20 with strain 45/20 utilized in cattle and sheep and H38 in cattle [8]. Due to their limitations in protective immunity as compared to the attenuated strains and their induction of persistent antibody titers, both are no longer utilized under field conditions.
The live vaccine B. melitensis Rev 1 (Rev 1) is currently utilized for the control of brucellosis in small ruminants. This strain was developed by Herzberg and Elberg in the mid-1950s and retains common characteristics of Brucella but is resistant to streptomycin and susceptible to penicillin G [9]. Subcutaneous or conjunctival immunization with Rev 1 confers protective immunity in small ruminants. However, Rev 1 vaccination stimulates an antibody response that reacts in serological tests, which cannot be differentiated from the humoral responses of infected animals. As B. melitensis can infect cattle, limited data have been reported that suggest that vaccination with Rev 1 has some efficacy in controlling infection with this Brucella species in cattle [10].
Due to the incubation period and potential latent infections, it is difficult to eradicate brucellosis by using serologic methods to detect and remove infected animals. The inclusion of vaccination programs to improve herd resistance is generally required to control the spread of the disease. To date, Rev 1 is the best available vaccine for the prevention of B. melitensis infection in small ruminants [9] and is typically administered to young animals (3–5 months old) at 0.5–2 × 109 colony-forming units (CFU) subcutaneously. Although a bacteremia occurs after vaccination, it has been reported that the vaccine strain is cleared in approximately 14 weeks in goats. Although a reduced dose of the Rev 1 vaccine (103–106 CFU) has been suggested for subcutaneous administration, it has been found to offer limited protection against disease and does not prevent abortions [11][12]. When administered to adult sheep or goats during pregnancy at 109 CFU, abortions and shedding of Rev 1 in milk are common [11][12]. This presents a challenge in endemic areas where mass vaccination is necessary for control and pregnant sheep and goats may need to be vaccinated despite the risk of adverse effects [13]. In addition to the disadvantages listed above, the strain is also virulent to humans, and zoonotic infections have occurred during vaccination from exposure to abortions or consumption of infected milk [14][15].
Administered subcutaneously, Rev 1 vaccine stimulates protective immunity against B. melitensis but can elicit long-lasting antibody responses that interfere with serological testing. In contrast, conjunctival administration of the vaccine confers immunity similar to the standard subcutaneous approaches but reduces the magnitude and persistence of serological responses. For this reason, conjunctival vaccination has been utilized in endemic areas, as it has less impact on serologic screening and facilitates control programs. When eradication is the ultimate goal of a control program, conjunctival vaccination of Rev 1 in adult animals is ideal for enhancing herd immunity and preventing B. melitensis infections. It has been hypothesized that Rev 1 vaccination may induce a high level of protective immunity for up to 4.5 years, which essentially is lifelong immunity for small ruminants in most production systems. This hypothesis that Rev 1 vaccination induces lifelong immunity has contributed to the belief that the vaccination of young stock is sufficient for adequate control of B. melitensis infection in small ruminants. However, this vaccination strategy is tenuous, and even developed countries have failed to control brucellosis in small ruminants with this approach. The failure of vaccination of young stock only could be due to (i) failure to obtain high vaccination coverage in a herd due to animal movement or introduction of unvaccinated animals; (ii) use of poor quality vaccines or products not maintained with appropriate cold chain conditions; and (iii) a possible decrease over time of protective immunity induced by vaccination. Therefore, vaccination of whole flocks is the only viable alternative to control B. melitensis infection in small ruminants under extensive control conditions characteristic of many developing countries [16].
To develop promising vaccines against brucellosis, it is critical to produce T helper 1 (Th1)-derived cytokines (interleukin-12, tumor necrosis factor α, interferon gamma γ) associated with cellular immunity and activation of macrophages, dendritic cells, and CD4+ and CD8+ T cells. T helper 2 (Th2) immune responses associated with humoral responses do not appear to have a major role in the clearance of infection [17]. A study has demonstrated that cytokines, such as IL-4 (Th2 cytokines) and IFN-γ (Th1 cytokines), stimulate different IgG subtypes (IgG1 and IgG2 antibodies, respectively) that may be indicative of differences in the immune response [17].

2. Brucella melitensis Vaccines in Small Ruminants

Of the 18 included publications, nine contained information only relevant to recombinant vaccines, one to a live B. melitensis vaccine, five to nanoparticle vaccines, two to subunit vaccines, and one to a DNA vaccine. The recombinant B. melitensis 16M hfq (16MΔhfq) strain induced humoral and cellular responses in mice after intraperitoneal vaccination (ip) with increased expression of IgG1, IgG2a, IFN-γ, and IL-4. The recombinant strain did not differ from Rev 1 in the induction of cytokine responses, was cleared at approximately eight weeks post-vaccination (PV), and demonstrated protective immunity that was slightly less than Rev 1 vaccination after experimental challenge with B. melitensis 16M at eight weeks PV. [18]. Another study utilized a B. melitensis TcfSR promoter (16MΔTcfSR) recombinant strain in which one of the two-component regulatory systems that allow host cells to detect environmental changes and adapt to Brucella infection was mutated. The recombinant induced a high level of protective immunity when challenged approximately 1 week after vaccine strain clearance. Vaccination did not induce humoral responses that interfered with serodiagnostic tests [19]. The M5-90ΔwboA recombinant is a reduced virulence, attenuated vaccine that induces reduced inflammatory responses as compared to the parental strain. The reduced virulence and safety of this recombinant were based on the observation that splenomegaly did not occur in a murine host. When compared to the parental strain, comparable protection to the parental strain was observed in mice after experimental challenge approximately 1 week after vaccine strain clearance. Humoral responses in vaccinated sheep and mice allowed for vaccinates to be distinguished from infected animals [20]. Others have demonstrated that a DNA vaccine based on pcDNA3.1, encoding the ORF of B. melitensis Omp25 and Opm31 genes, may be a viable vaccine candidate due to induction of humoral (IgG) and cellular (Th1 cytokines IFN-ɣ and Th2 cytokines IL-10) in mice. The DNA vaccine construct elicited cellular and humoral responses to B. melitensis antigens after four inoculations at 1-week intervals [21]. Vaccination of mice with nanoparticle B. melitensis and B. abortus vaccines conferred less protection than Rev 1 vaccination when experimentally challenged 1 month after the last of three oral vaccinations. Protection was correlated with a mixed Th1-Th17 response [22]. In a different study, the authors demonstrated that a different nanoparticle vaccine (Omp31-loaded N-trimethyl chitosan nanoparticles) induced Th1–Th17 immune responses in mice after three dosages delivered orally or two dosages administered ip. Lower antibody titers were observed in mice orally immunized as compared to ip [23]. When experimentally challenged with B. melitensis strain 16M at 1 month after vaccination, oral vaccinates had greater protection than intraperitoneal vaccinates but less protection than Rev 1 vaccinates. A third nanoparticle vaccine (based on poly lactic-co-glycolic acid nanoparticles 50:50 and containing oligopolysaccharide antigens) induced humoral responses in mice that increased after each inoculation. Experimental challenge with B. melitensis 2 weeks after the third inoculation demonstrated reduced splenic infection when compared to the control mice [24].
Subunit vaccines offer the advantages of better safety profiles, induction of humoral responses [25], and faster production with reduced costs [26]. Candidate subunit vaccines identified in this search included OMVs vaccines in either Poly (I:C) or 327 CpG + Montanide ISA adjuvant formulations. Humoral responses increased after two vaccine dosages with adjuvanted vaccines demonstrating the greatest responses. Spleenocytes demonstrated greater cytokine responses (IFN-γ and IL-2) in vitro after stimulation with OMV antigens [27]. Another study that used a recombinant protein-based subunit vaccine (Omp10, Omp28, L7/L12 combinations) alone or with Taishan Pinus massoniana pollen polysaccharide adjuvants (TPPPS) demonstrated increased humoral responses after inoculation, but the responses were greater in mice inoculated with a live B. melitensis M5 vaccine. Serum IL-2, IL-4, and IFN-γ were increased in the vaccinated mice. After experimental challenge at 4 weeks after vaccination, the mice inoculated with subunit vaccines containing all antigens and adjuvant had reductions in splenic infection that were similar to but less than the reductions observed in the mice inoculated with the live vaccine [28].
Unfortunately, most B. melitensis candidate vaccines have only been evaluated in murine models in which disease pathogenesis can be markedly different from what occurs in ruminant hosts. Murine models are inbred as compared to outbred domestic livestock hosts. There are significant differences in ruminant immunologic responses from those of mice, including the observation that ruminants have a high percentage of circulating T cells expressing γδ markers. Lastly, infection in mice is generally quantified by the evaluation of hepatic and splenic colonization, whereas in ruminant hosts, infection is predominantly within lymphatic tissues. These differences emphasize the need for the evaluation of brucellosis vaccine candidates in the species of interest to address research needs. In addition, some studies in murine models administer experimental challenges prior to the immune system returning to a senescent state, and therefore, colonization data might be influenced by nonspecific immune activation.

References

  1. Welburn, S.C.; Beange, I.; Ducrotoy, M.J.; Okello, A.L. The Neglected Zoonoses—The Case for Integrated Control and Advocacy. Clin. Microbiol. Infect. 2015, 21, 433–443.
  2. Godfroid, J.; DeBolle, X.; Roop, R.M.; O’Callaghan, D.; Tsolis, R.M.; Baldwin, C.; Santos, R.L.; McGiven, J.; Olsen, S.; Nymo, I.H.; et al. The quest for a true One Health perspective of brucellosis. Rev. Sci. Tech. 2014, 33, 521–538.
  3. Muendo, E.N.; Mbatha, P.M.; Macharia, J.; Abdoel, T.H.; Janszen, P.V.; Pastoor, R.; Smits, H.L. Infection of cattle in Kenya with Brucella abortus biovar 3 and Brucella melitensis biovar 1 genotypes. Trop. Anim. Health Prod. 2012, 44, 17–20.
  4. Gwida, M.; El-Gohary, A.; Melzer, F.; Khan, I.; Rösler, U.; Neubauer, H. Brucellosis in camels. Res. Vet. Sci. 2012, 92, 351–355.
  5. Mick, V.; Carrou, G.L.; Corde, Y.; Game, Y.; Jay, M.; Garin-Bastuji, B. Brucella melitensis in France: Persistence in wildlife and probable spillover from alpine ibex to domestic animals. PLoS ONE 2014, 9, e94168.
  6. Nicoletti, P. Vaccination. In Animal Brucellosis; Nielsen, K., Duncan, J.R., Eds.; CRC Press: Boca Raton, FL, USA, 1990; pp. 284–299.
  7. Roux, J. Brucella vaccines in humans. In Brucellosis; Madkour, M.M., Ed.; Butterworths: London, UK, 1989; pp. 244–249.
  8. Plommet, M.; Renoux, G.; Philppon, A.; Lorentz, C.; Gestin, J. Experimental brucellosis, Comparison of vaccine efficacy B19 and H38 vaccine. Ann. Vet. Res. 1970, 1, 189–201.
  9. Elberg, S.S.; Faunce, K., Jr. Immunization against Brucella infection. VI. Immunity conferred on goats by a nondependent mutant from a streptomycin-dependent mutant strain of Brucella melitensis. J. Bacteriol. 1957, 73, 211–217.
  10. Banai, M. Control of small ruminant brucellosis by use of Brucella melitensis Rev.1 vaccine: Laboratory aspects and field observations. Vet. Microbiol. 2002, 90, 497–519.
  11. Alton, G.G. Vaccination of goats with reduced doses of Rev.1 Brucella melitensis vaccine. Res. Vet. Sci. 1970, 2, 54–59.
  12. Blasco, J.M.; Molina-Flores, B. Control and eradication of Brucella melitensis infection in sheep and goats. Vet. Clin. N. Am. Food Anim. Pract. 2011, 27, 95–104.
  13. Blasco, J.M. A review of the use of B. melitensis Rev.1 vaccine in adult sheep and goats. Prev. Vet. Med. 1997, 31, 275–283.
  14. Vershilova, P. The use of live vaccine for vaccination of human beings against brucellosis in the USSR. Bull. World Health Organ. 1961, 24, 85.
  15. Pappas, G. The changing Brucella ecology: Novel reservoirs, new threats. Int. J. Antimicrob. Agents 2010, 36, S8–S11.
  16. FAO/WHO/OIE. Round Table on the Use of Rev.1 Vaccine in Small Ruminants and Cattle; Garin-Bastuji, B., Benkirane, A., Eds.; CNEVA: Paris, France, 1995.
  17. Pasquevich, K.A.; Estein, S.M.; Samartino, C.G.; Zwerdling, A.; Coria, L.M.; Barrionuevo, P.; Fossati, C.; Giambartolomei, G.; Cassataro, J. Immunization with recombinant Brucella species outer membrane protein Omp16 or Omp19 in adjuvant induces specific CD4+ and CD8+ T cells as well as systemic and oral protection against Brucella abortus infection. Infect. Immun. 2009, 77, 436–445.
  18. Zhang, J.; Guo, F.; Chen, C.; Li, Z.; Zhang, H.; Wang, Y.; Zhang, K.; Du, G.; Li, Y.; Wang, J.; et al. Brucella melitensis 16 M Δhfq attenuation confers protection against wild-type challenge in BALB/c mice. Microbiol. Immunol. 2013, 57, 502–510.
  19. Li, Z.; Zhang, J.; Zhang, K.; Fu, Q.; Wang, Z.; Li, T.; Zhang, H.; Guo, F.; Chen, C. Brucella melitensis 16MΔTcfSR as a potential live vaccine allows for the differentiation between natural and vaccinated infection. Exp. Ther. Med. 2015, 10, 1182–1188.
  20. Li, Z.-Q.; Shi, J.-X.; Fu, W.-D.; Zhang, Y.; Zhang, J.; Wang, Z.; Li, T.; Chen, C.; Guo, F.; Zhang, H. A Brucella melitensis M5-90 wboA deletion strain is attenuated and enhances vaccine efficacy. Mol. Immunol. 2015, 66, 276–283.
  21. Shojaei, M.; Tahmoorespur, M.; Soltani, M.; Sekhavati, M.H. Immunogenicity evaluation of plasmids encoding Brucella melitensis Omp25 and Omp31 antigens in BALB/c mice. Iran. J. Basic Med. Sci. 2018, 21, 957.
  22. Abkar, M.; Fasihi-Ramandi, M.; Kooshki, H.; Lotfi, A.S. Intraperitoneal immunization with Urease loaded N-trimethyl Chitosan nanoparticles elicits high protection against Brucella melitensis and Brucella abortus infections. Immunol. Lett. 2018, 199, 53–60.
  23. Abkar, M.; Fasihi-Ramandi, M.; Kooshki, H.; Lotfi, A.S. Oral immunization of mice with Omp31-loaded N-trimethyl chitosan nanoparticles induces high protection against Brucella melitensis infection. Int. J. Nanomed. 2017, 12, 8769.
  24. Maleki, M.; Salouti, M.; Shafiee Ardestani, M.; Talebzadeh, A. Preparation of a nanovaccine against Brucella melitensis M16 based on PLGA nanoparticles and oligopolysaccharide antigen. Artif. Cells Nanomed. Biotechnol. 2019, 47, 4248–4256.
  25. Ficht, T.A.; Kahl-McDonagh, M.M.; Arenas-Gamboa, A.M.; Rice-Ficht, A.C. Brucellosis: The case for live, attenuated vaccines. Vaccine 2009, 27, D40–D43.
  26. Fu, S.; Xu, J.; Li, X.; Xie, Y.; Qiu, Y.; Du, X.; Yu, S.; Bai, Y.; Chen, Y.; Wang, T.; et al. Immunization of mice with recombinant protein CobB or AsnC confers protection against Brucella abortus infection. PLoS ONE 2012, 7, e29552.
  27. Golshani, M.; Amani, M.; Amirzadeh, F.; Nazeri, E.; Siadat, S.D.; Nejati-Moheimani, M.; Arsang, A.; Bouzari, S. Evaluation of Poly (I: C) and combination of CpG ODN plus Montanide ISA adjuvants to enhance the efficacy of outer membrane vesicles as an acellular vaccine against Brucella melitensis infection in mice. Int. Immunopharmacol. 2020, 84, 106573.
  28. Zhu, L.; Wang, Q.; Wang, Y.; Xu, Y.; Peng, D.; Huang, H.; Hu, L.; Wei, K.; Zhu, R. Comparison of immune effects between Brucella recombinant Omp10-Omp28-L7/L1 proteins expressed in eukaryotic and prokaryotic systems. Front. Vet. Sci. 2020, 7, 576.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Public, Environmental & Occupational Health
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Alnakhli Naseer
,
Salman Mo
,
Steven C. Olsen
,
Brian McCluskey
View Times: 397
Revisions: 2 times (View History)
Update Date: 06 Dec 2023
Table of Contents
    1000/1000
    Hot Most Recent
    ScholarVision Creations
    Feedback